Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking
the enzymes necessary for cancer cell growth.
PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in
treating patients who have advanced cancer.